中国组织工程研究

中国组织工程研究 ›› 2026, Vol. 30 ›› Issue (18): 4594-4601.doi: 10.12307/2026.711

• 口腔组织构建 oral tissue construction • 上一篇    下一篇

雷洛昔芬对去势大鼠牙槽骨重吸收的影响

昝冰欣1，赵  昱1，代庆刚2，3   

  1. 1滨州医学院口腔医学院，山东省烟台市  264000；2上海交通大学医学院附属第九人民医院口腔第二门诊部，上海交通大学口腔医学院，国家口腔医学中心，国家口腔疾病临床医学研究中心，上海市  200000；3海南西部医院口腔医学中心，海南省儋州市  571700

  • 收稿日期:2025-04-27 接受日期:2025-09-05 出版日期:2026-06-28 发布日期:2025-12-02
  • 通讯作者: 代庆刚，博士，副主任医师，上海交通大学医学院附属第九人民医院口腔第二门诊部，上海交通大学口腔医学院，国家口腔医学中心，国家口腔疾病临床医学研究中心，上海市 200000；海南西部医院口腔医学中心，海南省儋州市 571700
  • 作者简介:昝冰欣，女，1998年生，河南省洛阳市人，汉族，滨州医学院在读硕士，主要从事颅颌面骨研究。
  • 基金资助:
    上海市自然科学基金项目(21ZR1436900)，项目负责人：代庆刚；上海交通大学医学院附属第九人民医院“交叉”研究基金项目(JYJC202411)，项目负责人：代庆刚；海南省自然科学基金项目(824MS152)，项目负责人：代庆刚

Effect of raloxifene on alveolar bone resorption in ovariectomized rats

Zan Bingxin1, Zhao Yu1, Dai Qinggang2, 3   

  1. 1Binzhou Medical University School of Stomatology, Yantai 264000, Shandong Province, China; 2The 2nd Dental Center, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Disease; Shanghai Key Laboratory of Stomatology, Shanghai 200000, China; 3Center of Stomatology, Hainan Hospital, Danzhou 571700, Hainan Province, China
  • Received:2025-04-27 Accepted:2025-09-05 Online:2026-06-28 Published:2025-12-02
  • Contact: Dai Qinggang, PhD, Associate chief physician, The 2nd Dental Center, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Disease; Shanghai Key Laboratory of Stomatology, Shanghai 200000, China; Center of Stomatology, Hainan Hospital, Danzhou 571700, Hainan Province, China
  • About author:Zan Bingxin, MS candidate, Binzhou Medical University School of Stomatology, Yantai 264000, Shandong Province, China
  • Supported by:
    Shanghai Natural Science Foundation, No. 21ZR1436900 (to DQG); “Interdisciplinary” Research Fund of Affiliated Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, No. JYJC202411 (to DQG); Hainan Provincial Natural Science Foundation, No. 824MS152 (to DQG)

PDF

13

摘要：

文题释义：
绝经后牙槽骨骨质疏松症：雌激素缺失会导致绝经后女性破骨细胞活性增强及骨转换速率加快，进而造成牙槽骨骨量减少和骨微观结构破坏。
选择性雌激素受体调节剂：对雌激素受体有高度亲和力，在不同的靶器官分别发挥雌激素受体激动剂和拮抗剂的作用。

背景：由于体内雌激素水平下降，绝经后女性罹患牙槽骨骨质疏松症的风险显著攀升。雷洛昔芬作为一种潜在的治疗手段，初步发现对牙槽骨骨质疏松具有积极影响。 
目的：探讨雷洛昔芬对去卵巢大鼠牙槽骨吸收的影响。 
方法：将45只雌性SD大鼠随机分为3组：假手术组、模型组以及雷洛昔芬组，后2组采用卵巢摘除造模，雷洛昔芬组大鼠术后腹腔注射10 μL盐酸雷洛昔芬(5 mg/kg)，在首次给药后2周重复注射1次，共计注射2次。术后2个月，采用Micro-CT扫描大鼠磨牙及牙槽骨，分析骨微结构参数：骨矿化密度、骨体积分数、骨小梁厚度、骨小梁数量以及骨小梁间隙，然后大鼠牙槽骨进行苏木精-伊红染色、骨钙素免疫组织化学染色以及抗酒石酸酸性磷酸酶染色。
结果与结论：①与模型组相比，雷洛昔芬组大鼠牙槽骨骨密度呈现上升趋势(P < 0.05)，雷洛昔芬组骨体积分数和骨小梁厚度均显著升高
(P < 0.05)，骨小梁间隙和骨小梁数量均显著降低(P < 0.05)；②苏木精-伊红染色显示，与模型组相比，雷洛昔芬组大鼠牙槽骨结构得到显著改善，新骨形成区域明显增多(P < 0.05)；③免疫组织化学染色显示，与模型组相比，雷洛昔芬组骨钙素阳性细胞数量显著增加(P < 0.05)，染色强度也明显增强；④抗酒石酸酸性磷酸酶染色显示，与模型组相比，雷洛昔芬组破骨细胞活性减弱，骨质流失减少。结果表明：雷洛昔芬能够显著抑制去势大鼠牙槽骨骨吸收，防止牙槽骨结构破坏，从而有效延缓牙槽骨骨质疏松的进展。
https://orcid.org/0009-0000-7457-4777(昝冰欣)

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

关键词: 绝经后骨质疏松症, 雷洛昔芬, 牙槽骨骨质疏松, 雌激素, 选择性雌激素受体调节剂

Abstract: BACKGROUND: Due to the decline in estrogen levels within the body, postmenopausal women face a significantly increased risk of developing alveolar bone osteoporosis. Raloxifene, as a potential treatment, has shown preliminary positive effects on alveolar bone osteoporosis.
OBJECTIVE: To study the effect of raloxifene on alveolar bone resorption in ovariectomized rats.
METHODS: Forty-five female Sprague-Dawley rats were divided into three groups: a sham-operated group, a model group, and a raloxifene group. Ovariectomy was performed to establish animal models in the latter two groups. Rats in the raloxifene group received intraperitoneal injections of 10 μL of raloxifene hydrochloride (5 mg/kg). The injection was repeated once 2 weeks after the first dose, and there were two injections in total. After 2 months, the rat molars and alveolar bone were scanned using Micro-CT to analyze bone microstructural parameters, including bone mineral density, bone volume fraction, trabecular thickness, trabecular number, and trabecular separation. Subsequently, alveolar bone samples were subjected to hematoxylin-eosin staining, immunohistochemical staining for osteocalcin, and tartrate-resistant acid phosphatase staining.
RESULTS AND CONCLUSION: (1) Compared with the model group, the raloxifene group exhibited an increasing trend in bone mineral density of the rat alveolar bone (P < 0.05). Bone volume fraction and trabecular thickness were significantly increased in the raloxifene group (P < 0.05), while trabecular separation and trabecular number were significantly decreased (P < 0.05). (2) Hematoxylin-eosin staining results showed that, compared with the model group, the alveolar bone structure of rats in the raloxifene group was significantly improved, with a marked increase in the number of new bone formation areas (P < 0.05). (3) Immunohistochemical staining results showed that, compared with the model group, the number of osteocalcin-positive cells in the raloxifene group was significantly increased (P < 0.05), and the staining intensity was also markedly enhanced. (4) In addition, tartrate-resistant acid phosphatase staining revealed that raloxifene significantly reduced bone loss by inhibiting the activity of osteoclasts. To conclude, raloxifene can significantly inhibit alveolar bone resorption in ovariectomized rats, prevent structural damage to the alveolar bone, and thereby effectively delay the progression of alveolar bone osteoporosis.


Key words: postmenopausal osteoporosis, raloxifene, alveolar bone osteoporosis, estrogen, selective estrogen receptor modulator 

中图分类号: